{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-014178","form_type":"8-K","ticker":"ATXI","cik":"0001644963","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.401468+00:00","generated_at":"2026-06-03T02:56:07.151085+00:00","sec_items":["1.01","3.02","3.03","8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Avenue Therapeutics raises $4.4M via warrant exercise inducement; issues new warrants","bullets":["Holders exercised 689,680 existing warrants at reduced price of $6.20/share for $4.4M gross proceeds.","In exchange, Company issued new Series C and Series D warrants to purchase up to 689,680 shares each at $6.20.","Series C warrants exercisable for 5 years; Series D for 18 months; Placement agent got warrants at $7.75.","Proceeds used for general corporate purposes; H.C. Wainwright acted as exclusive placement agent.","Existing warrants (Oct 2022, Nov 2023, Jan 2024) had exercise prices of $116.25, $22.545, and $22.545."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-014178","json":"https://secwatch.observer/filing/0001437749-24-014178.json","markdown":"https://secwatch.observer/filing/0001437749-24-014178.md","text":"https://secwatch.observer/filing/0001437749-24-014178.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1644963/000143774924014178/0001437749-24-014178-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1644963/000143774924014178/atxi20240501_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T02:56:07.151085+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"edbda14adccf2c26fc378d6c7a50eb3df11663f5","claim":"AVENUE THERAPEUTICS, INC. entered into Inducement Letters with certain investors (the October 2022 Investors, November 2023 Investors, and January 2024 Investors) valued at approximately $4.4 million (effective 2024-04-28).","evidence_excerpt":"On April 28, 2024, Avenue Therapeutics, Inc. (the “ Company ”) entered into inducement offer letter agreements (the “ Inducement Letters ”) with (i) certain investors (the “ October 2022 Investors ”) that hold certain outstanding warrants to purchase up to an aggregate of 27,271 shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), originally issued to the October 2022 Investors on October 11, 2022 (the “ October 2022 Warrants ”); (ii) certain investors (the “ November 2023 Investors ”) that hold certain outstanding Series A and Series B warrants to purchase up to an aggregate of 221,333 shares of Common Stock, originally issued to the November 2023 Investors on October 31, 2023 (the “ November 2023 Warrants ”); and (iii) certain investors (the “ January 2024 Investors ” and, collectively with the October 2022 Investors and November 2023 Investors, the “ Holders ”) that hold certain outstanding Series A and Series B warrants to purchase up to an agg","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1644963/000143774924014178/0001437749-24-014178-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain investors (the October 2022 Investors, November 2023 Investors, and January 2024 Investors)"},{"label":"Value","value":"approximately $4.4 million"},{"label":"Effective","value":"2024-04-28"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}